Biogen’s Aducanumab Falls Hard At Panel Review, Leaving US FDA In A Tight Spot

FDA Advisory Committee Feature image
Aducanumab lacks substantial evidence of efficacy for Alzheimer's treatment, a US FDA panel said.

More from US FDA Performance Tracker

More from Regulatory Trackers